SciClone Appoints Wilson W. Cheung as Chief Financial Officer

SciClone Appoints Wilson W. Cheung as Chief Financial Officer 
FOSTER CITY, CA -- (Marketwired) -- 07/15/13 --  SciClone
Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the appointment
of Wilson W. Cheung as Chief Financial Officer and Senior Vice
President, Finance. Mr. Cheung is an experienced senior financial and
international accounting executive with broad experience spanning
financial management, SEC and SOX 404 financial reporting for
publicly traded international companies, as well as corporate
governance and compliance, operations management, corporate
development and investor relations. Mr. Cheung will report to
Friedhelm Blobel, Ph.D., Chief Executive Officer, and will be based
in the Company's Foster City, CA headquarters.  
"Wilson has extensive experience in managing financial operations and
compliance for commercial, publicly traded companies and has a deep
understanding of companies operating in China in highly regulated,
competitive and fast changing environments," said Dr. Blobel. "His
international, multi-industry experience will be especially valuable
as our Company implements strategies to drive our long-term growth,
expand the market opportunities for ZADAXIN(R), develop the potential
of our growing portfolio of differentiated products, and strengthen
our standing as a US-based, China-focused specialty pharmaceutical
company. I am particularly pleased with the significant strengthening
of SciClone's management team in the US and China over the last
several quarters, and believe that Wilson will be a great addition to
our executive team." 
"I believe that SciClone is an exciting, growth-oriented specialty
pharmaceutical company with excellent prospects for delivering
impressive financial results and building shareholder value," said
Mr. Cheung. "I appreciate the opportunity to work with the highly
dedicated finance teams in the US and China to maintain timely and
high quality financial reporting, and to help strengthen SciClone's
market success and reputation within the investor community."  
Mr. Cheung served most recently as Chief Compliance Officer, Asia
Pacific of Velti plc, a global mobile marketing and advertising
software-as-a-service provider, and previously as Chief Financial
Officer, where he took the company public on its Nasdaq IPO, raised
over $400 million in equity and debt and oversaw global finance and
accounting functions and investor relations. Prior to Velti, Mr.
Cheung was Chief Financial Officer and Corporate Secretary at AXT,
Inc., a California-based, publicly traded manufacturer of high
performance semiconductor substrates, with a major presence in China,
where he led the finance and operations teams. Mr. Cheung previously
held senior financial positions in telecommunications company
InterWAVE Communications International Ltd. (now Alvarion, Ltd), and
at Yahoo!, Deloitte, where he advised US companies operating in
China, and at KPMG in their Los Angeles, Hong Kong and Beijing
offices. Mr. Cheung holds a B.A. from the University of California,
Los Angeles (UCLA), and is a Certified Director of Corporate
Governance from UCLA's Executive Program. He is a California
Certified Public Accountant (inactive), and speaks English, Cantonese
and Mandarin.  
About SciClone 
SciClone Pharmaceuticals is a US-based, China-focused specialty
pharmaceutical company with a product portfolio of therapies for
oncology, infectious diseases and cardiovascular, urological,
respiratory, and central nervous system disorders. SciClone's
ZADAXIN(R) (thymalfasin) is approved in over 30 countries and may be
used for the treatment of hepatitis B (HBV), hepatitis C (HCV) and
certain cancers, and as a vaccine adjuvant, according to the local
regulatory approvals. Besides ZADAXIN, SciClone markets about 14
mostly partnered products in China, including Depakine(R), the most
widely prescribed broad-spectrum anti-convulsant in China;
Tritace(R), an ACE inhibitor for the treatment of hypertension;
Stilnox(R), a leading hypnotic for the short-term treatment of
insomnia (marketed as Ambien(R) in the US); and Aggrastat(R), a
recently-launched interventional cardiology product. SciClone is also
pursuing the registration of several other therapeutic products in
China. SciClone is headquartered in Foster City, California. For
additional information, please visit  
Forward-Looking Statements  
This press release contains forward-looking statements regarding
expected financial results and expectations. Readers are urged to
consider statements that include the words "may," "will," "would,"
"could," "should," "might," "believes," "estimates," "projects,"
"potential," "expects," "plans," "anticipates," "intends,"
"continues," "forecast," "designed," "goal," "unaudited,"
"approximately" or the negative of those words or other comparable
words to be uncertain and forward-looking. These statements are
subject to risks and uncertainties that are difficult to predict and
actual outcomes may differ materially. Please also refer to other
risks and uncertainties described in SciClone's filings with the SEC.
All forward-looking statements are based on information currently
available to SciClone and SciClone assumes no obligation to update
any such forward-looking statements. 
Ambien, Depakine, Stilnox and Tritace are registered trademarks of
Sanofi and/or its affiliates. 
Aggrastat is a registered trademark of Medicure International Inc. in
the United States, and Iroko Cardio LLC or Merck & Co., Inc. in
numerous other countries. 
SciClone, SciClone Pharmaceuticals, the SciClone Pharmaceuticals
design, the SciClone logo and ZADAXIN are registered trademarks of
SciClone Pharmaceuticals, Inc. in the United States and numerous
other countries. 
Corporate Contact 
Jane Green
Press spacebar to pause and continue. Press esc to stop.